Osteopore Ltd. (AU:OSX)
ASX:OSX
Top Page
Osteopore Ltd.
(Sydney:OSX)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.01
â–²(0.00% Upside)
Action:ReiteratedDate:03/01/26
The score is primarily constrained by weak financial performance—continued net losses, negative operating/free cash flow, and negative equity—despite strong revenue growth and a reduction in debt. Valuation signals are limited by a negative P/E and lack of dividend data, while technical analysis cannot be meaningfully assessed due to missing indicators.
Positive Factors
Sustained Revenue Growth
Consistent multi-year revenue growth (~1.5M to ~3.1M from 2020–2025) signals expanding clinical adoption and market traction for Osteopore’s bioresorbable implants. This trend supports durable top-line momentum and provides a base for scaling operations and improving unit economics.
Negative Factors
Persistent Net Losses
Large recurring net losses and negative operating/free cash flow demonstrate ongoing cash burn and reliance on external financing. This structural shortfall constrains the company’s ability to self-fund expansion, increases dilution/refinancing risk, and can limit long-term strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Consistent multi-year revenue growth (~1.5M to ~3.1M from 2020–2025) signals expanding clinical adoption and market traction for Osteopore’s bioresorbable implants. This trend supports durable top-line momentum and provides a base for scaling operations and improving unit economics.
Read all positive factors
Osteopore Ltd. (OSX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$3.38M
Dividend YieldN/A
Average Volume (3M)2.16M
Price to Earnings (P/E)―
Beta (1Y)1.46
Revenue Growth5.52%
EPS Growth49.25%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.01
Shares Outstanding562,501,830
10 Day Avg. Volume675,672
30 Day Avg. Volume2,156,422
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.70
Price to Sales (P/S)0.40
P/FCF Ratio-0.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Osteopore Ltd. Business Overview & Revenue Model
Company Description
Osteopore Limited designs, develops, and markets bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery applications in Singapore, Australia, and internationally. Its technology fabricates specific micro-structured...
How the Company Makes Money
Osteopore generates revenue primarily through the sale of its biodegradable implants and scaffolds to hospitals, clinics, and medical practitioners. The company's revenue model includes direct sales of its products, which are often covered by heal...
Osteopore Ltd. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
22
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.06M | 2.81M | 2.22M | 1.69M | 1.11M |
| Gross Profit | 1.62M | 2.37M | 1.64M | 1.27M | 811.64K |
| EBITDA | -1.92M | -2.34M | -4.35M | -3.97M | -3.38M |
| Net Income | -3.72M | -3.35M | -4.87M | -4.22M | -3.62M |
Balance Sheet | |||||
| Total Assets | 2.77M | 3.13M | 3.34M | 3.62M | 6.01M |
| Cash, Cash Equivalents and Short-Term Investments | 626.97K | 638.50K | 1.16M | 1.35M | 4.55M |
| Total Debt | 198.80K | 1.33M | 1.09M | 74.18K | 106.71K |
| Total Liabilities | 4.50M | 2.83M | 2.91M | 1.51M | 633.40K |
| Stockholders Equity | -1.73M | 306.22K | 432.60K | 2.11M | 5.37M |
Cash Flow | |||||
| Free Cash Flow | -2.57M | -3.10M | -3.74M | -4.06M | -4.00M |
| Operating Cash Flow | -2.56M | -3.09M | -3.74M | -4.00M | -3.81M |
| Investing Cash Flow | -10.79K | -14.59K | -7.37K | -63.98K | -194.62K |
| Financing Cash Flow | 2.67M | 2.63M | 3.58M | 896.32K | -485.88K |
Osteopore Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$190.01M | -47.06 | -3.80% | ― | 16.93% | 76.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$21.08M | -7.11 | -19.01% | ― | 6.77% | -8.45% | |
43 Neutral | AU$3.38M | -0.33 | 346.27% | ― | 5.52% | 49.25% | |
43 Neutral | AU$37.10M | -4.21 | -52.26% | ― | -36.68% | 79.41% | |
42 Neutral | AU$84.50M | -14.80 | -40.65% | ― | 700.00% | 26.88% | |
41 Neutral | AU$206.19M | -12.98 | -44.80% | ― | 42.05% | -0.84% |
* Healthcare Sector Average
AU:OSX
Osteopore Ltd.
0.01
-0.02
-66.67%
AU:OCC
Orthocell Ltd
0.76
-0.50
-39.68%
AU:ARX
Aroa Biosurgery Ltd
0.55
0.17
44.74%
AU:IME
ImExHS Limited
0.39
0.04
11.43%
AU:EMD
Emyria Ltd
0.05
0.02
58.62%
AU:ALA
Arovella Therapeutics Limited
0.07
>-0.01
-2.78%
Osteopore Ltd. Corporate Events
Osteopore lifts revenue to record high but loss widens on growth investment
Feb 27, 2026
Osteopore Limited reported record revenue of $3.06 million for the year ended 31 December 2025, an 11% increase driven by stronger traction across core markets and product segments. Despite this top-line growth, the company’s net loss after ...
Osteopore Seeks ASX Quotation for 50 Million New Shares
Feb 11, 2026
Osteopore Limited has lodged an application with the ASX for quotation of 50,000,000 ordinary fully paid shares under code OSX, with an issue date of 11 February 2026. The move expands the company’s quoted share base, signalling a material c...
Osteopore Launches 3D Printing Services to Tap Rapidly Growing Healthcare Market
Feb 9, 2026
Osteopore Limited has launched a state-of-the-art 3D printing services line in Singapore, offering pre-surgical planning models and sterilised intra-operative cutting jigs to both public and private hospitals. The move, driven by direct demand fro...
Osteopore Issues Additional Unquoted Convertible Notes
Feb 6, 2026
Osteopore Limited has notified the market of the issue of additional unquoted convertible notes, identified under ASX code OSXAM, as part of its capital structure on 6 February 2026. The relatively small issuance of 10 convertible notes signals a ...
Osteopore Completes Full A$5m Drawdown of First Tranche of Convertible Notes
Feb 6, 2026
Osteopore Limited has completed the final A$500,000 drawdown of Tranche 1 of its 4.0% redeemable convertible notes under a subscription agreement with Advance Opportunities Fund and Advance Opportunities Fund I, bringing the total nominal amount i...
Osteopore Seeks ASX Quotation for 70 Million New Shares
Feb 3, 2026
Osteopore Limited has applied to the Australian Securities Exchange for quotation of 70 million new fully paid ordinary shares, to be traded under its existing ticker, OSX, from 3 February 2026. The sizeable securities issuance signals a significa...
Osteopore Expands Hong Kong Presence With New Design Partnership and Global Centre of Excellence
Jan 30, 2026
Osteopore has entered a partnership with the Tam Shiu Anatomical Modelling Laboratory at the University of Hong Kong to advance digital design and workflows for anatomical models, surgical guides, cutting jigs and the digital reconstruction of bon...
Osteopore Seeks ASX Quotation for 20 Million New Shares
Jan 27, 2026
Osteopore Ltd has applied to the ASX for quotation of 20 million new fully paid ordinary shares, to be traded under its existing ticker, OSX. The share issuance, dated 27 January 2026, will expand the company’s quoted capital base, potential...
Osteopore Targets Greater Bay Area via Exclusive Hong Kong Orthopaedic Deal
Jan 22, 2026
Osteopore Limited has clarified details of its exclusive agreement with MontsMed Hong Kong Company Limited to introduce its custom and off-the-shelf orthopaedic implant products into Hong Kong. While Hong Kong itself is not considered a major bone...
Osteopore Enters Hong Kong with Exclusive Orthopaedic Distribution Deal
Jan 21, 2026
Osteopore Limited has signed an exclusive three-year distribution agreement, with an option for a one-year extension, with MontsMed Hong Kong Company Limited to introduce its custom and off-the-shelf orthopaedic products into Hong Kong, initially ...
Osteopore Seeks ASX Quotation for 10 Million New Shares
Jan 20, 2026
Osteopore Limited has applied to the ASX for quotation of 10 million new fully paid ordinary shares, with the securities to be issued and quoted on 20 January 2026 under the ticker OSX. The move expands the company’s listed share base and ma...
Osteopore Seeks ASX Quotation for 50 Million New Shares
Jan 19, 2026
Osteopore Limited has applied to the Australian Securities Exchange for quotation of 50 million new fully paid ordinary shares, to be traded under its existing ticker, OSX. The securities were issued on 16 January 2026, signaling a significant exp...
Osteopore Seals Exclusive Majeton Deal to Drive China Expansion
Jan 16, 2026
Osteopore Limited has entered an exclusive commercialisation agreement with Majeton to distribute its dental, orthodontic and maxillofacial regenerative implants across China, Hong Kong and Macau, marking a strategic move to penetrate the Greater ...
Osteopore Seals RMB 12m Exclusive China Distribution Deal with Majeton
Jan 15, 2026
Osteopore Limited has signed a multi-year, exclusive distribution agreement worth more than RMB 12 million with Majeton Pte Ltd to commercialise its dental, orthodontic and maxillofacial products in China, Hong Kong and Macau. The deal, which incl...
Osteopore Issues Additional Unquoted Convertible Notes for Funding Flexibility
Jan 14, 2026
Osteopore Limited has notified the market of the issue of five unquoted convertible notes under the security code OSXAM, with the issue dated 14 January 2026. The small-scale issuance of these convertible notes indicates the company is continuing ...
Osteopore Issues Cleansing Notice for Next $250,000 Tranche of Convertible Notes
Jan 14, 2026
Osteopore Limited has issued a cleansing notice in connection with a new $250,000 sub‑tranche (ST18 of T1) of redeemable convertible notes subscribed for by Advance Opportunities Fund and Advance Opportunities Fund I under an existing subscr...
Osteopore Draws Further A$250,000 from Tranche 1 of Convertible Notes Facility
Jan 14, 2026
Osteopore Limited has drawn a further A$250,000 sub-tranche (ST18) from Tranche 1 of its 4.0% redeemable convertible notes facility with Advance Opportunities Fund and Advance Opportunities Fund I, taking total subscriptions under Tranche 1 to A$4...
Osteopore Secures Exclusive Heparan Sulphate Licence to Target High-Growth Bone Regeneration Market
Jan 7, 2026
Osteopore Limited has signed an exclusive 15-year licensing agreement with Accelerate Technologies, the commercialisation arm of Singapore’s A*STAR, to use a Heparan Sulphate bioactive technology platform designed to significantly accelerate...
Advance Opportunities Fund I Ceases to Be Substantial Holder in Osteopore
Dec 30, 2025
Advance Opportunities Fund I has lodged a notice under Australia’s Corporations Act stating it has ceased to be a substantial shareholder in Osteopore Limited. The filing, dated 30 December 2025, indicates that the fund’s relevant inte...
Osteopore Ltd. Announces Quotation of New Securities on ASX
Dec 12, 2025
Osteopore Ltd. has announced the quotation of 16,949,152 new fully paid ordinary securities on the Australian Securities Exchange (ASX) as of December 11, 2025. This move is part of the company’s strategic efforts to enhance its capital stru...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.